GenoMed, Inc. finalizes Letter of Agreement with Muna, Inc. to Obtain DNA Specimens for the Study of Diseases within the Hispanic Population
January 25, 2002--GenoMed Inc.--(“the Company” or “GenoMed”) (National Quotation Bureau’s Pink Sheets Symbol: GMED) a St. Louis, Missouri based medical genomics biotechnology company, announced today that GenoMed has entered into a Letter of Agreement with Muna, Inc., a Florida company, to obtain blood samples from Hispanic patients with a variety of common diseases.
Dr. Leo A. Gosser, Ph.D., CEO of Muna, Inc., has established a substantial network of physicians in southern Florida to assist in the collection of blood samples within the Hispanic and other populations. GenoMed will assist Muna, Inc. in establishing a computer database for the collection of clinical information specific to each patient sample. The samples will be made anonymous as soon as feasibly possible during the collection process.
David Moskowitz, Chief Medical Officer of GenoMed, stated, "We are pleased to be working with Dr. Gosser and Muna, Inc. to obtain these samples. The incidence of type 2 diabetes and its complications are especially high within the Hispanic community. Each ethnic group must be screened for its own specific set of disease-causing genes, since the genes vary according to ethnic group.” Dr. Moskowitz added, “To leave any one group out would be to delay optimal healthcare for that group. Our intention is to encompass each of the human populations without prejudice in our search for disease genes."
Dr. Leo Gosser, states, “We are pleased to establish this relationship with GenoMed, and to be on the cutting edge of genotyping research.”
About GenoMed
GenoMed was founded with the sole purpose of translating knowledge of disease genomics into improved patient treatments. The Company is screening millions of genotypes for association with various diseases in an effort to identify novel therapeutic targets for existing prescription drugs. GenoMed expects to generate revenues by licensing disease gene research data to the pharmaceutical industry to serve as targets for new drugs, and to clinical diagnostic laboratories for the early diagnosis of disease. The Company has filed initial patent applications with the United States Patent and Trademark Office that document improved patient outcomes in pilot trials.
For additional information please visit www.genomedics.com and/or contact Craig Hall @ (941) 366-6677 or email at chall@floridafunds.com.
. |
